Personalized risk messages fail to boost colorectal cancer screening participation in trial
- medicalxpress.com language
- 2025-09-02 04:00 event
- 2 weeks ago schedule

Domain EYEION.com for sale! This premium domain is available now at Kadomain.com
Past a smoldering pile of trash and two bleating goats, through a doorway beginning to buckle beneath the weight of the bricks above, is a darkened room where a skeletal, 70-year-old man lies on a pillowless bed above a floor littered with trash.
In the night, when all that glows on this hilltop is the moonlight and all that moves are branches tickled by a soft breeze, the tumult returns. The old woman grows convinced her house is on fire and, panicked, drags the table, chairs and the rest of her few worldly possessions, outside. Unable to calm his mother, her son knows just one way to end it.
A first-of-its-kind clinical trial has shown it's possible to identify breast cancer survivors who are at higher risk of their cancer coming back due to the presence of dormant cancer cells and to effectively treat these cells with repurposed, existing drugs. The research, led by scientists from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine, is published in Nature Medicine.
Researchers have identified a neurochemical signature that sets Parkinson's disease apart from essential tremor—two of the most common movement disorders, but each linked to distinct changes in the brain.
Researchers from the University of Birmingham, U.K., have identified bioactive peptide sequences in the PEPITEM molecule, and demonstrated the biological activity of the full PEPITEM molecule in counteracting key changes caused by osteoporosis.
In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.
As the UK and other NATO nations dramatically increase defense spending to counter growing global aggressions, one under-recognized aspect of security debates is the role of the arms industry.
Researchers at the University of Southampton examining worldwide variations in funding for cancer research say there's a pressing need to invest more in lower income countries.
Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session at the ESC Congress 2025.
A randomized controlled trial aimed to determine whether providing information on patient risk for advanced colorectal neoplasia (ACN) to patients and providers affects colorectal cancer (CRC) screening uptake.
Routine Helicobacter pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding in patients hospitalized for myocardial infarction (MI), according to late-breaking research presented in a Hot Line session at the ESC Congress 2025 and simultaneously published in JAMA.
A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected atrial fibrillation. Clinical decisions should therefore be guided by individual factors. The findings were presented by Dr. Nina Becher, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, in a hotline session at the annual congress of the European Society of Cardiology (ESC) in Madrid.
An analysis of patient-operated ECGs from the EAST—AFNET 4 trial revealed: A low AF burden below 6% in the first year of early rhythm control therapy was associated with low cardiovascular event rates during the subsequent 4 years of follow-up. Patients with a higher AF burden on early rhythm control suffered more AF-related events. The findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht University, in a hotline session at the annual congress of the European Society of Cardiology (ESC) in Madrid.
Cervical cancer remains one of the most common malignancies in women, ranking as the fourth most prevalent cancer worldwide. Most cases are caused by high-risk strains of human papillomavirus (HPV), particularly HPV16 and HPV18.
Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session at the ESC Congress 2025 and simultaneously published in the American Heart Journal.
Pulsed field ablation did not have superior efficacy to radiofrequency ablation in patients with drug-resistant paroxysmal (intermittent) atrial fibrillation, according to results from a late-breaking trial presented in a Hot Line session at the ESC Congress 2025.
Dual antiplatelet therapy after cardiac bypass surgery is no more effective than acetylsalicylic acid alone and also increases the risk of serious bleeding. This is shown in a study by researchers at Karolinska Institutet and the University of Gothenburg published in the journal the New England Journal of Medicine.
Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session at ESC Congress 2025 and simultaneously published in the New England Journal of Medicine.
A suspected perpetrator who can barely remember his name, several traffic violations committed by a woman in her mid-fifties who is completely unreasonable and doesn't understand her behavior—should such cases be brought before a court? And how does the state deal with people who commit acts of violence without meaning to?